Contributions
Abstract: P705
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: Gait problem is one of the most common main complaints in patients with multiple sclerosis (MS) as well as neuromyelitis optica spectrum disorder (NMOSD). The 12-item MS walking scale (MSWS-12) is a commonly adopted patient-reported measure of the impact of MS on the individual's walking ability, and has been translated and validated in various languages. However, it has not been validated for Korean MS patients. In addition, its applicability has not been evaluated for patients with NMOSD. The aim of this study was to adapt and validate the Korean version of MSWS-12 for the Korean population with MS and NMOSD.
Methods: Patients with MS (n=30, M:F=19:11) and NMOSD (n=30, M:F=6:24) were enrolled between December 2015 and January 2017. The MSWS-12 questionnaire was translated into Korean language. The validity of MSWS-12 was determined by examining correlations with Expanded Disability Status Scale (EDSS), timed 25-foot walk (T25FW), and Korean versions of Patient Health Questionnaire (PHQ-9), Multiple Sclerosis Impact Scale (MSIS-29), Short Form Health Survey (SF-36), and Fatigue Severity Scale (FSS), using nonparametric Spearman coefficient. A p value lower than 0.05 was considered to be statistically significant.
Results: Mean age was 36.2±9.0 (ranged 20.1-52.8, median 37.0) years in MS and 41.2±11.9 (ranged 19.8-67.2, median 37.5) years in NMOSD. Mean disease duration was 7.1±5.4 years (ranged 2 months-18.8 years, median 5.7 years) in MS and 8.4±6.5 years (ranged 8 months-20.2 years, median 7.4 years) in NMOSD. Median EDSS score was 2.5 (ranged 0-6.5) in MS and 3.0 (ranged 0-7.5) in NMOSD. The mean total MSWS-12 score was 24.6±12.9 (ranged 12-52, median 23) in MS and 26.7±15.3 (ranged 12-60, median 22) in NMOSD patients. Among demographic factors, age and disease duration were correlated with MSWS-12 scores in MS, while only age was correlated with MSWS-12 scores in NMOSD patients. Among the measures, MSWS-12 values of MS patients were significantly correlated with EDSS (Spearman's coefficient 0.89), T25FW (0.63), PHQ-9 (0.37), MSIS (0.76), and SF-36 (-0.30), but not with FSS. In NMOSD patients, MSWS-12 scores were significantly correlated with all measures: EDSS (0.73), T25FW (0.55), PHQ-9 (0.58), MSIS (0.89), SF-36 (-0.74), and FSS (0.63).
Conclusion: The Korean version of MSWS-12 appears a valid and reliable scale that can be used for Korean patients with MS. In addition, MSWS-12 can be applicable to the patients with NMOSD.
Disclosure: Woojun Kim: nothing to disclose. Jae-Won Hyun: nothing to disclose. So-Young Huh: nothing to disclose. Na Young Park: nothing to disclose. Hyunmin Jang: nothing to disclose. Su-Hyun Kim has received a grant from the National Research Foundation of Korea. Ho Jin Kim has lectured, consulted and received honoraria from Bayer Schering Pharma, Biogen, Celltrion, Esai, Genzyme, HanAll BioPharma, MedImmune, Merck Serono, Novartis, Teva-Handok and UCB; received a grant from the Ministry of Science & ICT; accepted research funding from Genzyme, Kael-GemVax, Merck Serono, Teva-Handok and UCB; serves on a steering committee for MedImmune; is a coeditor for the Multiple Sclerosis Journal - Experimental, Translational and Clinical, and an associated editor for the Journal of Clinical Neurology.
Abstract: P705
Type: Poster Sessions
Abstract Category: Clinical aspects of MS - Clinical assessment tools
Background: Gait problem is one of the most common main complaints in patients with multiple sclerosis (MS) as well as neuromyelitis optica spectrum disorder (NMOSD). The 12-item MS walking scale (MSWS-12) is a commonly adopted patient-reported measure of the impact of MS on the individual's walking ability, and has been translated and validated in various languages. However, it has not been validated for Korean MS patients. In addition, its applicability has not been evaluated for patients with NMOSD. The aim of this study was to adapt and validate the Korean version of MSWS-12 for the Korean population with MS and NMOSD.
Methods: Patients with MS (n=30, M:F=19:11) and NMOSD (n=30, M:F=6:24) were enrolled between December 2015 and January 2017. The MSWS-12 questionnaire was translated into Korean language. The validity of MSWS-12 was determined by examining correlations with Expanded Disability Status Scale (EDSS), timed 25-foot walk (T25FW), and Korean versions of Patient Health Questionnaire (PHQ-9), Multiple Sclerosis Impact Scale (MSIS-29), Short Form Health Survey (SF-36), and Fatigue Severity Scale (FSS), using nonparametric Spearman coefficient. A p value lower than 0.05 was considered to be statistically significant.
Results: Mean age was 36.2±9.0 (ranged 20.1-52.8, median 37.0) years in MS and 41.2±11.9 (ranged 19.8-67.2, median 37.5) years in NMOSD. Mean disease duration was 7.1±5.4 years (ranged 2 months-18.8 years, median 5.7 years) in MS and 8.4±6.5 years (ranged 8 months-20.2 years, median 7.4 years) in NMOSD. Median EDSS score was 2.5 (ranged 0-6.5) in MS and 3.0 (ranged 0-7.5) in NMOSD. The mean total MSWS-12 score was 24.6±12.9 (ranged 12-52, median 23) in MS and 26.7±15.3 (ranged 12-60, median 22) in NMOSD patients. Among demographic factors, age and disease duration were correlated with MSWS-12 scores in MS, while only age was correlated with MSWS-12 scores in NMOSD patients. Among the measures, MSWS-12 values of MS patients were significantly correlated with EDSS (Spearman's coefficient 0.89), T25FW (0.63), PHQ-9 (0.37), MSIS (0.76), and SF-36 (-0.30), but not with FSS. In NMOSD patients, MSWS-12 scores were significantly correlated with all measures: EDSS (0.73), T25FW (0.55), PHQ-9 (0.58), MSIS (0.89), SF-36 (-0.74), and FSS (0.63).
Conclusion: The Korean version of MSWS-12 appears a valid and reliable scale that can be used for Korean patients with MS. In addition, MSWS-12 can be applicable to the patients with NMOSD.
Disclosure: Woojun Kim: nothing to disclose. Jae-Won Hyun: nothing to disclose. So-Young Huh: nothing to disclose. Na Young Park: nothing to disclose. Hyunmin Jang: nothing to disclose. Su-Hyun Kim has received a grant from the National Research Foundation of Korea. Ho Jin Kim has lectured, consulted and received honoraria from Bayer Schering Pharma, Biogen, Celltrion, Esai, Genzyme, HanAll BioPharma, MedImmune, Merck Serono, Novartis, Teva-Handok and UCB; received a grant from the Ministry of Science & ICT; accepted research funding from Genzyme, Kael-GemVax, Merck Serono, Teva-Handok and UCB; serves on a steering committee for MedImmune; is a coeditor for the Multiple Sclerosis Journal - Experimental, Translational and Clinical, and an associated editor for the Journal of Clinical Neurology.